The Binaytara Foundation Welcomes Dr. Sri Tantravahi as Co-Chair of the BTF Education Academy

The Binaytara Foundation (BTF) is pleased to welcome Dr. Sri Tantravahi as the new Co-Chair of the BTF Education Academy. Dr. Tantravahi will work closely with Dr. Sid Yadav, who will also continue serving as Co-Chair. Drs. Tantravahi and Yadav will engage with other members, recruit new members as needed, and shape the future of BTF’s education efforts.

Dr. Sri Tantravahi will Co-Chair the BTF Education Academy.

“It is my honor to serve as a Co-Chair of the BTF Education Academy,” said Dr. Tantravahi. “I am looking forward to working with Sid and will do my part to advance the mission of the foundation.”

About the BTF Education Academy

The BTF Education Academy hosts multiple conferences on cancer-related topics each year and offers online courses and webcasts for CME credit. One upcoming conference is the 2022 Cellular Therapy Conference in Salt Lake City, September 9-10, a CME-accredited oncology conference featuring lectures and discussions with leading experts in cellular therapies.

Additionally, the Education Academy publishes an open-access, peer-reviewed medical journal, with a focus on disparities in cancer care both in the US and globally. They publish a wide range of scientific articles focused on improving the care of cancer patients by minimizing or eliminating barriers to care delivery. To find out how many CME credits you can earn, submit a manuscript to the journal, or register for a conference, please visit education.binayfoundation.org.

The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal.

The goal of the Binaytara Foundation is to improve healthcare in resource-poor communities and improve cancer care worldwide by educating healthcare providers and community members. They do this by advocating for better access to care and innovating program models and services that improve access to care.

Additionally, the Binaytara Foundation provides continuing education to physicians and other health care providers through the Education Academy. CME-accredited oncology and hematology conferences provide physicians with the most recent and cutting-edge research in cancer care. Through these educational activities, physicians and health care providers are able to provide their patients with the best care in order to improve patient outcomes.

Binaytara Foundation oncology and hematology conferences take place year-round at a variety of locations, both in-person and virtually, around the United States. These conferences attract nationally and regionally well-known experts as speakers and aim to target cancer health professionals from all around the world. 

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago